Pathologic immune effector cells

Pathologic immune effector cells in the context of allogeneic hematopoietic cell transplantation (allo-HCT) refer to donor-derived immune cells, primarily alloreactive T cells, that recognize recipient tissues as foreign and initiate an inflammatory attack (Zeiser & Blazar, 2017, N Engl J Med). This biological process is the primary driver of Graft-versus-Host Disease (GvHD), a significant complication of allo-HCT where donor cells attack the host's skin, liver, and gastrointestinal tract (StatPearls, 2023). While donor T cells are essential for the Graft-versus-Leukemia (GvL) effect, which prevents cancer relapse, the pathologic subset specifically mediates harmful systemic inflammation (Watkins et al., 2021, J Clin Oncol). Therapeutic strategies focus on depleting or modulating these cells; for instance, graft engineering platforms like Orca-T aim to precisely remove these effector cells while preserving regulatory T cells to maintain immune homeostasis (Orca Bio, 2024). Pharmacological agents such as ruxolitinib (a JAK1/2 inhibitor) and abatacept (a CTLA-4 immunoglobulin) are also used to inhibit the activation and signaling of these pathologic populations to prevent or treat GvHD (Jagasia et al., 2020, Blood). These interventions must be carefully balanced to avoid excessive immunosuppression, which can lead to opportunistic infections or the loss of the GvL effect. Monitoring of these cells often involves tracking surface markers like CD3, CD4, and CD8, as well as soluble biomarkers like ST2 and REG3α that indicate tissue damage (Levine et al., 2017, Lancet Haematol).

Other names

Alloreactive T cellsPathogenic T cellsDonor effector T cellsGvHD-inducing cellsConventional T cells (Tconv)

Depletion or inhibition of donor-derived alloreactive T cells to prevent host tissue attack while maintaining graft-versus-tumor activity.